BioEclipse Therapeutics
San Francisco
About BioEclipse Therapeutics
BioEclipse Therapeutics is a clinical-stage oncology company that develops immuno-oncology therapeutics using its proprietary technology. Its mission is to improve clinical outcomes and the quality of life for all cancer patients and to be at the forefront of turning cancer into a curable disease. The company has harnessed a refined understanding of the human immune system, gaining insights into the reasons the body’s defense system so often turns a blind eye to the presence of cancerous cells and tumors. In response, BioEclipse Therapeutics pairs activated immune cells with an adapted oncolytic virus that selectively infects and kills malignant cells.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $15.7M
- Funding stage: Early Stage Venture
- Last round: Grant (Apr 2022)
- Website: bioeclipse.com
- Phone: (408)809-1030
Industries & Categories
Biotechnology, Health Care, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/bioeclipse-therapeutics-26429 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.